AI in drug development: The real hurdle is implementation

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about how the real hurdle in clinical research lies in effectively integrating AI.

Stelzer discusses the need for greater coordination within the pharmaceutical industry, particularly between life sciences and software engineering and explains how bridging the cultural divide can significantly enhance the adoption of emerging technologies like AI.

Of course, the conversation also touches upon the importance of collaboration, which can positively empower pharmaceutical companies to overcome existing challenges and drive significant advancements in drug development.

You can listen to episode 176a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!